Breakthrough trial offers first hope for children with Vanishing White Matter diseaseA team of researchers from the Amsterdam Leukodystrophy Center at Amsterdam UMC, led by Prof. Marjo van der Knaap, has published the first clinical evidence that the drug guanabenz may alter the course of vanishing white matter disease (VWM), a devastating childhood neurodegenerative disorder for which no effective treatment previously existed. The findings from the neuroscientists of this phase 1/2 trial have now been published in The Lancet Neurology.
Kim de Kleijn and Femke Feringa receive Alzheimer Nederland Research Talent AwardTwo Alzheimer researchers from Amsterdam Neuroscience have received the Research Talent Award from Alzheimer Nederland. The award supports young, talented researchers at the beginning of their careers in continuing and expanding their research.
Jentien Vermeulen awarded Dekker grant for research on cardiovascular disease and psychosisPeople with psychosis have an increased risk of cardiovascular disease, but these often young individuals are frequently identified too late. Dr. Jentien Vermeulen (Psychiatrist and senior researcher) is investigating who is at extra risk. She is developing a calculation tool that will enable healthcare professionals to monitor these individuals earlier. Together with patients, she translates this into an appropriate treatment plan.
Subscribe to our Newsletter
Become an official Amsterdam Neuroscience member to receive the latest news.
